Page 201 - 80 guidelines for the treatment of malaria_opt

ANNEX 9. Treatment of Plasmodium vivax, P. ovale and P. malariae infections

91. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clinical Infectious Diseases, 2004,
39:1336–1345.
92. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Safety, 2004, 27:25–61.
93. Leslie T et al. Compliance with 14-day primaquine therapy for radical cure of vivax
malaria - a randomized placebo-controlled trial comparing unsupervised with supervised
treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004,
98:168–173.
94. Walsh DS et al. Efficacy of monthly Tafenoquine for prophylaxis of Plasmodium vivax
and multidrug-resistant P. falciparum malaria. Journal of Infectious Diseases, 2004, 190:
1456–1463.
95. Chotivanich K et al. Ex-vivo short-term culture and developmental assessment of
Plasmodium vivax. Transactions of the Royal Society of Tropical Medicine and Hygiene,
2001, 95: 677–680.
96. Tasanor O et al. An in vitro system for assessing the sensitivity of Plasmodium vivax to
chloroquine. Acta Tropica, 2002, 83:49–61.
97. Russell BM et al. Simple in vitro assay for determining the sensitivity of Plasmodium
vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic.
Antimicrobial Agents and Chemotherapy, 2003, 47:170–173.
98. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated
falciparum malaria. Geneva, World Health Organization, 2003.
99. Galappaththy GNL, Omari AAA, Tharyan P. Primaquine for preventing relapses in people
with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews, 2007, Issue 1
(Article No. CD004389). doi: 10.1002/14651858

A9

187